On account of increasing number of cases related to high blood pressure and diabetes, growth in pipeline of peripheral arterial disease is anticipated in the next few years. One of the main causes of peripheral arterial disease is smoking, which leads to the building up of plaque inside the arteries that carry oxygen rich blood. As per the data provided by World Health Organization in 2015, nearly 1.1 billion people were addicted to smoking. Moreover, increasing number of people are being diagnosed with high blood pressure, diabetes and other lifestyle related diseases on account of unhealthy dietary habits, growing pressure at work, etc. On the back of these factors, growth in pipeline of peripheral arterial disease therapeutics is anticipated over next few years.
According to the National Institute of Heart, Lung and Blood Institute, peripheral arterial disease is caused by formation of plaque in arteries, which can translocate to other organs such as head and limbs. Fat, cholesterol, calcium and other fibrous tissues are responsible for the formation of plaque, in turn resulting in, Atherosclerosis, a condition that transpires in plaque build-up. It also leads to hardening and narrowing of the arteries, which limits the supply of oxygen-rich blood to the body. It generally occurs in legs, but it can also occur in arteries that carry blood to the head, arms, kidney and stomach. Sometimes, blockage in blood flow can cause numbness and pain in that area of the body, in turn amplifying the chances of infection to the affected limbs and, in severe cases, it can cause gangrene.
In October 2015, CorVascular Diagnostics, LLC entered into a collaboration and distribution agreement with Vasamed Inc., for the development of diagnostics through SensiLase PAD-IQ technology. Vasamed Inc. provided the dependable, reproducible measurement of tissue perfusion of the extremities particularly in patients having combined peripheral arterial disease and diabetes. In June 2016, Highmark Health, Allegheny Health Network and Avinger, Inc., entered into a collaboration to evaluate Pantheris, Avinger’s novel image-guided atherectomy device for the treatment of peripheral arterial disease (PAD). The partnership was a part of Highmark Health’s VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovation Program. In February 2017, Profusa Inc. and North Carolina State University’s ASSIST Center entered into collaboration for developing an ultrathin flexible-patch reader worn on the skin for continuous wireless monitoring of tissue oxygen in patients undergoing treatment for peripheral arterial disease (PAD), which has been awarded a $1.5 million in Phase II Small Business Innovation Research (SBIR) grant, administered by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). In November 2016, Reliq Health Technologies Inc. signed an agreement with Hamilton Health Sciences and McMaster University in Hamilton for the improvement of health outcomes for patients with peripheral arterial disease.
Some of the companies having a pipeline of peripheral arterial disease therapeutics include Bayer AG, Juventas Therapeutics, Inc., Proteon Therapeutics, Inc., Humacyte, Inc., Veryan Medical Ltd., SurModics, Inc., Acotec Scientific Co., Ltd, Spectranetics Corporation, Cardionovum GmbH.